Understand the source comparison
Best Peptides for Complex Regional Pain: Research Comparison
BPC-157 VEGF modulation, NO signalling, endothelial repair Restored blood flow 85% vs 40% in ischaemia models; promotes functional angiogenesis 200–500 mcg/day (animal models, SC) Strongest evidence for microvascular repair. Addresses trophic changes and oedem
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF modulation, NO signalling, endothelial repair
- Restored blood flow 85% vs 40% in ischaemia models; promotes functional angiogenesis
- 200–500 mcg/day (animal models, SC)
- Strongest evidence for microvascular repair. Addresses trophic changes and oedema
- Cerebrolysin
- BDNF/CNTF neurotrophic support, microglial modulation
- Reduced spinal microglial activation 40% in nerve injury models
- 5–30 mL IV (clinical), dose-dependent
- Best-supported for central sensitisation. Clinical data in neuropathic pain
- Thymosin Beta-4
- Actin sequestration, angiogenesis, nerve regeneration
- Improved capillary density 60% in ischaemic tissue; promotes functional vessel formation
- 2–10 mg twice weekly (SC)
- Targets vascular and nerve repair. Indirect CRPS relevance via tissue healing
- Dihexa
- HGF mimetic, synaptogenesis, c-Met receptor agonism
- 7-fold increase in dendritic spine density; reverses maladaptive plasticity
- 1–5 mg/day oral (preclinical)
- Promising for CNS plasticity reversal. Early-stage research only
- KPV
- NF-κB inhibition, anti-inflammatory, cytokine suppression
- Reduced TNF-alpha 70% in inflammation models; blocks inflammatory transcription
- 500 mcg–2 mg/day (SC or oral)
- Anti-inflammatory at genetic level. Mechanistically sound but no CRPS-specific trials
- Thymalin
- Mast cell stabilisation, T-cell regulation, immune modulation
- Reduced mast cell tryptase 35% in allergic models; dampens NGF release
- 10–50 mg IM (clinical protocols)
- Addresses NGF-driven pain amplification. Indirect evidence only